A61K 40/4232
Tumor necrosis factors [tnf] or cd70
Official title: {Tumor necrosis factors [TNF] or CD70}
A61K40/4232 (Tumor necrosis factors [tnf] or cd70) appears on 59 US grants and 162 published applications in this corpus.
Search patents in A61K- Granted patents
- 59
- Published applications
- 162
- Assignees
- 76
- Inventors
- 345
- Latest grant
- 22 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 1 |
| 2004 | 0 | 1 |
| 2005 | 0 | 1 |
| 2006 | 1 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 1 |
| 2009 | 1 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 1 | 3 |
| 2014 | 1 | 0 |
| 2015 | 1 | 1 |
| 2016 | 0 | 2 |
| 2017 | 2 | 1 |
| 2018 | 0 | 8 |
| 2019 | 0 | 8 |
| 2020 | 5 | 13 |
| 2021 | 9 | 22 |
| 2022 | 7 | 19 |
| 2023 | 7 | 25 |
| 2024 | 8 | 21 |
| 2025 | 5 | 22 |
| 2026 | 9 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods for manufacturing genetically engineered CAR-T cells22 Sep 2026US 12,742,184 B2Crispr Therapeutics AG
- Antigen-binding protein targeting CD70 and use thereof1 Sep 2026US 12,721,893 B2
- Methods of manufacturing CAR-T cells1 Sep 2026US 12,723,268 B2Crispr Therapeutics AG
- Combination therapy using a chimeric antigen receptor16 Jun 2026US 12,653,850 B2Novartis AG
- Chimeric antigen receptor targeting BCMA and use thereof9 Jun 2026US 12,649,785 B2National Cancer Center
- CD70 CAR-T Compositions and Methods for Cell-based Therapy24 Sep 2026US 2026/0285995 A1Intellia Therapeutics, Inc.
- Base editing proteins and uses thereof27 Aug 2026US 2026/0250650 A1
- Therapeutic base editing30 Jul 2026US 2026/0216245 A1The J. David Gladstone Institute, A Testamentary Trust Established Under the Will of J. David Gladst
- Cxcr3 overexpression in car-nk cells primes migration/homing into the tumor microenvironment2 Jul 2026US 2026/0183396 A1Dana-Farber Cancer Institute, Inc.
- Cd70-targeted cars and engineered cells comprising same and related methods25 Jun 2026US 2026/0174853 A1Juno Therapeutics, Inc.
Most cited
By later US patents
- Gene therapy759US 5,399,346 AThe United States of America as represented by the Department of Health and Human Services · 1995
- Materials and methods for engineering cells and uses thereof in immuno-oncology14US 10,736,919 B2Crispr Therapeutics AG · 2020
- Materials and methods for engineering cells and uses thereof in immuno-oncology11US 10,857,184 B2Crispr Therapeutics AG · 2020
- Materials and methods for engineering cells and uses thereof in immuno-oncology9US 10,729,725 B2Crispr Therapeutics AG · 2020
- Materials and methods for engineering cells and uses thereof in immuno-oncology9US 10,881,689 B2Crispr Therapeutics AG · 2021